Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Blueprint Medicines Corp (BPMC)

Blueprint Medicines Corp (BPMC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,841,375
  • Shares Outstanding, K 59,831
  • Annual Sales, $ 180,080 K
  • Annual Income, $ -644,090 K
  • 60-Month Beta 0.63
  • Price/Sales 15.88
  • Price/Cash Flow N/A
  • Price/Book 4.47
Trade BPMC with:

Options Overview Details

View History
  • Implied Volatility 57.04% ( -2.28%)
  • Historical Volatility 49.25%
  • IV Percentile 22%
  • IV Rank 19.65%
  • IV High 128.36% on 08/16/22
  • IV Low 39.60% on 12/23/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 88
  • Put/Call OI Ratio 0.97
  • Today's Open Interest 6,178
  • Open Int (30-Day) 6,277

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -2.67
  • Number of Estimates 11
  • High Estimate -2.27
  • Low Estimate -2.87
  • Prior Year -0.99
  • Growth Rate Est. (year over year) -169.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.78 +19.99%
on 11/09/22
49.04 -0.22%
on 12/02/22
+2.83 (+6.14%)
since 11/02/22
3-Month
40.78 +19.99%
on 11/09/22
79.40 -38.38%
on 09/08/22
-23.99 (-32.90%)
since 09/02/22
52-Week
40.78 +19.99%
on 11/09/22
111.78 -56.23%
on 12/23/21
-49.58 (-50.33%)
since 12/02/21

Most Recent Stories

More News
Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ACAD : 15.76 (+2.74%)
BPMC : 48.93 (+3.03%)
Blueprint Medicines (BPMC) Up 3.7% Since Last Earnings Report: Can It Continue?

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BPMC : 48.93 (+3.03%)
BMY : 81.13 (+0.31%)
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM

Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.

ANGN : 0.9200 (+12.20%)
SNDX : 25.07 (+0.16%)
BPMC : 48.93 (+3.03%)
IMCR : 60.58 (+1.00%)
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug...

BPMC : 48.93 (+3.03%)
Blueprint Medicines to Present at Upcoming Investor Conferences

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

BPMC : 48.93 (+3.03%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

BPMC : 48.93 (+3.03%)
Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark

Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.

RHHBY : 41.0800 (-0.15%)
BPMC : 48.93 (+3.03%)
AVIR : 4.80 (+0.42%)
AKRO : 45.46 (-0.50%)
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 11.16% and 51.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

BPMC : 48.93 (+3.03%)
HSKA : 65.34 (-1.07%)
Blueprint Medicines: Q3 Earnings Snapshot

Blueprint Medicines: Q3 Earnings Snapshot

BPMC : 48.93 (+3.03%)
Drug/Biotech Stocks' Q3 Earnings on Nov 1: PFE, LLY & More

Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.

PFE : 50.91 (-0.33%)
LLY : 374.76 (+1.20%)
INCY : 83.13 (+3.04%)
EXEL : 17.39 (+2.05%)
BPMC : 48.93 (+3.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.

See More

Key Turning Points

3rd Resistance Point 52.15
2nd Resistance Point 50.60
1st Resistance Point 49.76
Last Price 48.93
1st Support Level 47.37
2nd Support Level 45.82
3rd Support Level 44.98

See More

52-Week High 111.78
Fibonacci 61.8% 84.66
Fibonacci 50% 76.28
Fibonacci 38.2% 67.90
Last Price 48.93
52-Week Low 40.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar